REFRACTORY BURKITT LYMPHOMA
Clinical trials for REFRACTORY BURKITT LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY BURKITT LYMPHOMA trials appear
Sign up with your email to follow new studies for REFRACTORY BURKITT LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo therapy offers hope for Tough-to-Treat lymphomas
Disease control OngoingThis study tests a combination of two drugs—nivolumab and lenalidomide—in people with non-Hodgkin or Hodgkin lymphoma that has returned or stopped responding to treatment. The goal is to find the safest dose and see how well the drugs work together. About 36 adults with specific …
Matched conditions: REFRACTORY BURKITT LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: David Bond, MD • Aim: Disease control
Last updated May 26, 2026 12:07 UTC
-
Promising lymphoma combo trial pulled before it began
Disease control TerminatedThis study was designed to test whether combining three drugs—rituximab, venetoclax, and bortezomib—could shrink tumors in people with a fast-growing blood cancer called diffuse large B-cell lymphoma that had come back or stopped responding to standard therapy. The trial was with…
Matched conditions: REFRACTORY BURKITT LYMPHOMA
Phase: PHASE2 • Sponsor: Rutgers, The State University of New Jersey • Aim: Disease control
Last updated May 26, 2026 12:04 UTC
-
New cocktail targets tough lymphoma cancers
Disease control OngoingThis early-phase study tests a combination of three drugs (obinutuzumab, venetoclax, and lenalidomide) in 22 adults with B-cell non-Hodgkin lymphoma that has come back or stopped responding to treatment. The main goal is to find the safest dose and see if the combination can shri…
Matched conditions: REFRACTORY BURKITT LYMPHOMA
Phase: PHASE1 • Sponsor: Beth Christian • Aim: Disease control
Last updated May 22, 2026 13:53 UTC
-
New combo therapy aims to boost immune attack on tough lymphomas
Disease control OngoingThis phase 2 trial tests whether adding varlilumab to nivolumab helps people with aggressive B-cell lymphomas that have returned or not responded to standard therapy. About 54 participants will receive either nivolumab alone or nivolumab plus varlilumab. The goal is to see if the…
Matched conditions: REFRACTORY BURKITT LYMPHOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 11, 2026 20:40 UTC